Therapeutic Drug Monitoring of HIV-Protease Inhibitors to Assess Noncompliance
- 1 October 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 24 (5), 579-587
- https://doi.org/10.1097/00007691-200210000-00001
Abstract
To determine plasma concentration ratio limits (CORALS) for HIV-protease inhibitors outside of which random plasma concentrations reflect partial compliance or noncompliance. In the absence of a gold standard for measuring compliance and to avoid complex techniques, measuring plasma concentrations may be an objective and easy way to check noncompliance. Pharmacokinetic curves after observed ingestion were recorded in patients on steady-state indinavir 800 mg TID (n = 22), ritonavir 400 mg/saquinavir 400 mg BID (n = 22, ritonavir; n = 17, saquinavir hard-gel capsules), or nelfinavir 750 mg TID (n = 4) or 1250 mg BID (n = 4). Concentration ratios were calculated by dividing the measured concentration by the median population value at the corresponding sampling time. Limits were based on the minimum P05 (5th percentile) and maximum P95 of these ratios found during the sampling interval. With these limits the authors determined (1) the proportion of patients falsely judged as noncompliers after observed ingestion, (2) discrimination between compliers and noncompliers, and (3) the absolute percentage of noncompliers. To judge the last two elements, two sets of random plasma samples were included: (1) samples sent in by the physician on suspicion of noncompliance (indinavir, n = 42; nelfinavir, n = 22;) or from a study population stating imperfect compliance in a questionnaire (ritonavir/saquinavir, n = 11); (2) control samples sent in routinely for monitoring therapeutic levels (indinavir, n = 41; nelfinavir, n = 201) or drawn from patients who stated perfect compliance in the questionnaire (ritonavir/saquinavir, n = 35). The following CORALS were found: indinavir 3.3; nelfinavir 2.1; ritonavir 1.9; saquinavir 2.3. In 31% to 55% of the patients suspected of noncompliance a plasma concentration ratio outside these limits was found. If a ratio was outside the limits, there was a 68% to 88% chance that that plasma sample belonged to a patient suspected of noncompliance, compared with the controls (all Chi-squared tests P By using concentration ratio limits (CORALS), plasma samples of protease inhibitors with values outside these limits are highly indicative of partial or noncompliance.Keywords
This publication has 34 references indexed in Scilit:
- Evaluation of the Patient Medication Adherence Questionnaire As a Tool for Self-Reported Adherence Assessment in HIV-Infected Patients on Antiretroviral RegimensHIV Research & Clinical Practice, 2001
- Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studiesAIDS, 2000
- The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudineAIDS, 2000
- Monitoring Adherence to HIV TherapyArchives of Internal Medicine, 1999
- The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic responseAIDS, 1999
- Rate of HIV-1 RNA rebound upon stopping antiretroviral therapyAIDS, 1999
- Antiviral Effect and Pharmacokinetic Interaction between Nevirapine and Indinavir in Persons Infected with Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 1999
- The Electronic Medication Event MonitorClinical Pharmacokinetics, 1997
- Assessing drug compliance using longitudinal marker data, with application to AIDSStatistics in Medicine, 1994
- How often is medication taken as prescribed? A novel assessment techniqueJAMA, 1989